Therapeutic effect of sodium‑glucose cotransporter 2 inhibitor and benazepril on diabetic nephropathic rats

  • Authors:
    • Feiyan Liu
    • Yan Zhu
    • Jie He
    • Huimin Chen
    • Caixia Cao
    • Di Xiong
    • Ying Zhou
    • Ling Hu
  • View Affiliations

  • Published online on: November 8, 2022     https://doi.org/10.3892/etm.2022.11683
  • Article Number: 747
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to compare the therapeutic effect of sodium/glucose cotransporter 2 (SGLT2) inhibitor and benazepril on diabetic nephropathy (DN) rats and provide a potential novel agent for the clinical treatment of DN. The DN model was established on rats. Animals were dosed orally with SGLT2 and benazepril daily for 4 weeks. The pathological state of renal tissues were evaluated using hematoxylin and eosin, Masson and periodic acid‑Schiff staining. The change in the morphology of renal tissues was observed through transmission electron microscopy. Western blotting was utilized to determine the expression level of TGF‑β, N‑terminal fragment of the B‑type natriuretic peptide precursor (NT‑proBNP) and matrix metalloproteinase‑9 (MMP‑9). The expression level of endothelin 1 (ET‑1), von Willebrand factor (vWF), collagen (col)‑I and α smooth muscle actin (α‑SMA) in renal tissues was visualized using immunohistochemical assay. Significant pathological changes in the glomerular basement membrane, mesangial membrane, renal tubules, lumen, renal interstitial region and renal tubular epithelial cells were observed in DN rats, accompanied by increased collagen fibers. SGLT2 inhibitor treatment demonstrated more alleviatory effects on the pathological changes of renal tissues compared with benazepril. Compared with control, TGF‑β and NT‑proBNP were upregulated in DN rats, accompanied by the downregulation of MMP‑9, ET‑1, vWF, col‑I and α‑SMA, which were markedly reversed by treatment with SGLT2 inhibitor and benazepril. Compared with benazepril, the effects of SGLT2 inhibitor on the expression level of TGF‑β, NT‑proBNP, MMP‑9, ET‑1, vWF, col‑I and α‑SMA were more significant. Overall, SGLT2 inhibitor demonstrated an increased therapeutic effect against DN rats compared with benazepril by regulating cytokines, renal fibrosis and extracellular matrix degradation.

Related Articles

Journal Cover

December-2022
Volume 24 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu F, Zhu Y, He J, Chen H, Cao C, Xiong D, Zhou Y and Hu L: Therapeutic effect of sodium‑glucose cotransporter 2 inhibitor and benazepril on diabetic nephropathic rats. Exp Ther Med 24: 747, 2022
APA
Liu, F., Zhu, Y., He, J., Chen, H., Cao, C., Xiong, D. ... Hu, L. (2022). Therapeutic effect of sodium‑glucose cotransporter 2 inhibitor and benazepril on diabetic nephropathic rats. Experimental and Therapeutic Medicine, 24, 747. https://doi.org/10.3892/etm.2022.11683
MLA
Liu, F., Zhu, Y., He, J., Chen, H., Cao, C., Xiong, D., Zhou, Y., Hu, L."Therapeutic effect of sodium‑glucose cotransporter 2 inhibitor and benazepril on diabetic nephropathic rats". Experimental and Therapeutic Medicine 24.6 (2022): 747.
Chicago
Liu, F., Zhu, Y., He, J., Chen, H., Cao, C., Xiong, D., Zhou, Y., Hu, L."Therapeutic effect of sodium‑glucose cotransporter 2 inhibitor and benazepril on diabetic nephropathic rats". Experimental and Therapeutic Medicine 24, no. 6 (2022): 747. https://doi.org/10.3892/etm.2022.11683